Study of Pomalidomide with Rituximab and Immunotherapy for DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (pomalidomide, rituximab, and an immunotherapy called anti-PD-1) for people with diffuse large B-cell lymphoma that has not responded or has come back after two prior treatments. The goal is to see if this combination can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have diffuse large B-cell lymphoma confirmed by a biopsy, with lymphoma that did not fully go away or came back after two rounds of treatment.
- You are willing to use effective birth control during the study and for 6 months after (if you or your partner could become pregnant).
- You do not have certain severe health problems like uncontrolled heart failure or a bleeding disorder.
- You do not have an active autoimmune disease or a history of organ or stem cell transplant from another person.
- You have not had any active infection needing antibiotics or other treatment in the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two drugs (pomalidomide and rituximab) can help prevent lymphoma from coming back after initial treatment. It is for younger patients with high-risk DLBCL who responded well to their first therapy.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial tests a three-drug combination (pomalidomide, an anti-CD20 antibody, and prednisone) to treat certain slow-growing B-cell lymphomas that have never been treated before. The goal is to see if this combination works better than standard approaches.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Diffuse Large B-cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.